The use of amitraz (N1-(2,4-dimethylphenyl)-N-[(2,4-dimethylphenyl)imino)-methyl]-N-methylmethanimidamide) in demodecosis in dogs.
Amitraz topically applied as an 0.025 or 0.05% aqueous suspension once or twice weekly for up to 8 weeks cured 3 cases of generalised squamopapular to pustular demodectic mange and effectively controlled the condition in a fourth dog. Three of these dogs were Dobermans in which the disease was refractory to standard therapy with ronnel. A single wash in 0.025% amitraz suspension was sufficient to cure each of 5 dogs affected with localized demodecosis within 2 to 4 weeks. At these dose levels the drug is non toxic and non irritant to skin and mucous membranes. Recommendations for the use of amitraz include a thorough prewash of the entire skin surface with soap and water followed by application of the drug suspension with vigorous scrubbing, the compound then being allowed to dry on the animal's skin. The availability of amitraz therapy appears to provide a favourable prognosis for the control of severe long standing mange in the dog.
D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D007306:Insecticides / Q000627:therapeutic use*; D008924:Mite Infestations / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D012867:Skin / Q000469:parasitology; D014052:Toluidines / Q000627:therapeutic use*
D007306:Insecticides; D014052:Toluidines; C014983:amitraz